drugset / Trial / NCT01785160

Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir

NCT01785160

Phase 1 Completed 25 enrolled Boehringer Ingelheim
Non-randomizedCrossoverOpen-labelTreatment

Summary

The primary objective of this trial is to investigate effect of faldaprevir on steady state pharmacokinetics of raltegravir. The assessment of safety and tolerability will be an additional objective of this trial.

Timeline

Start
2013-02
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Faldaprevir Small molecule Oral
Subject Raltegravir Other / unclassified Oral

Indications

No indication recorded.